Date, Location, and Type of Meeting

The 27th Annual General Meeting was held on Wednesday, August 26, 2026, at 1:00 P.M. (IST) through Video Conferencing (VC)/Other Audio-Visual Means (OAVM) Facility. The meeting concluded at 2:40 P.M. (IST).

Attendance at the AGM

71 members attended the meeting virtually.

Directors Present:

  • Mrs. Pratibha Pilgaonkar - Managing Director and Chairperson of CSR Committee
  • Mr. Parag Sancheti - Executive Director & CEO
  • Mr. K G Ananthakrishnan - Independent Director and Chairperson of Nomination and Remuneration Committee, and Stakeholders Relationship Committee
  • Mr. Milind Patel - Independent Director and Chairperson of Audit Committee
  • Mr. Shantanu Rastogi - Non-Executive Director

Directors Absent:

Mr. Venkat Changavalli (Chairman of the Board), Mr. Varun Talukdar (Non-Executive Director), and Dr. Pradnya Saravade (Independent Director) were unable to attend due to exigencies.

Other Attendees:

  • Mr. Nitin Jajodia - Chief Financial Officer
  • Mr. Sagar Oak - Senior Vice President - Corporate Development & Strategy
  • Mrs. Deepashree Tanksale - Company Secretary
  • Mr. Manoj Dama - Representative of M/s. Deloitte Haskins & Sells LLP, Chartered Accountants (Statutory Auditor)
  • Mr. Sunny Gogiya - Representative of M/s. SGGS & Associates, Practicing Company Secretary (Scrutinizer)

Summary of Proposed Resolutions and Implications

The meeting considered nine resolutions:

Ordinary Business:

1. Adoption of Audited Standalone Financial Statements for FY 2025-26

2. Adoption of Audited Consolidated Financial Statements for FY 2025-26

3. Declaration of final dividend on equity shares for FY 2025-26

4. Re-appointment of Mrs. Pratibha Pilgaonkar (DIN: 00401516) as Director liable to retire by rotation

Special Business:

5. Approval of remuneration payable to Non-executive Independent Directors

6. Approval of Rubicon Research Limited Stock Options Plan 2026 for eligible employees

7. Extension of the Stock Options Plan 2026 to eligible employees of Subsidiary(ies)

8. Appointment of M/s. BNP & Associates, Company Secretaries, as Secretarial Auditors

9. Approval of Scheme of Merger of wholly owned subsidiary KIA Health Tech Private Limited with Rubicon Research Limited under Section 233 of the Companies Act, 2013

Voting Process and Methods Used

The remote e-voting facility was provided through NSDL, commencing at 9:00 a.m. on Saturday, August 22, 2026, and ending at 5:00 p.m. on Tuesday, August 25, 2026. The cut-off date for voting was Wednesday, August 19, 2026. Since remote e-voting was made available, there was no voting by show of hands at the meeting.

Key Voting Outcomes

The document states that the consolidated results of the Remote e-Voting and e-Voting at the AGM will be separately disclosed to the Stock Exchanges in due course. Specific voting numbers and percentages are not provided in this summary.

Scrutinizer's Role and Findings

Mr. Sunny Gogiya of M/s. SGGS & Associates, Practicing Company Secretary, served as the Scrutinizer for both remote e-voting and e-voting at the AGM. The scrutinizer's report was to be received after the meeting conclusion.

Compliance with Laws and Regulations

The meeting was conducted in compliance with the provisions of the Companies Act, 2013, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and relevant circulars issued by the Ministry of Corporate Affairs. The webcast facility was provided to members, and the proceedings were recorded for availability on the company's website.

Financial and Operational Highlights Presented

Mr. Sagar Oak, Senior Vice President - Corporate Development & Strategy, presented an overview of the company's performance (Annexure A), which included:

  • FY26 Revenue from Operations: ₹17,540 million (37% growth)
  • FY26 Net Profit after Tax: ₹2,467 million
  • ROACE: 36% (pre-tax, on average capital excluding cash)
  • Strong regulatory track record with zero 483 observations at Canada R&D (April 2026) and Thane R&D HQ (March 2025)
  • Manufacturing capabilities across multiple facilities including 35,000 sft facility in Thane and 13,000 sft nasal & inhalation center in Toronto

Names and Roles of Signatories

The document was signed by Mrs. Deepashree Tanksale, Company Secretary and Compliance Officer (M. No.: A28132), on behalf of Rubicon Research Limited.